• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Biogen: Let the Situation Cool Off a Bit Before Buying

There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
By JAMES "REV SHARK" DEPORRE
Jul 06, 2018 | 11:47 AM EDT
Stocks quotes in this article: BIIB, SRPT, ESALY

There are few diseases as cruel as Alzheimer's. I watched my mother deteriorate from it for years before she passed away from its ravages.

Many others have had this experience so it was uplifting to see the headlines this morning that Biogen (BIIB) and partner Eisai (ESALY) have announced positive Phase II results for a drug that treats Alzheimer's at an early stage.

Eisai's Chief Clinical Officer Lynn Kramer, M.D. stated, "This is the first late-stage anti-amyloid antibody study to successfully achieve statistically significant results at 18 months, further validating the amyloid hypothesis."

The study of 856 patients bodes well for the drug called BAN2401 but there is much more work to be done to bring the drug to fruition. Full details of the study will be announced at the Alzheimer's Association International Conference (AAIC) on July 22-26 or possibly at a later conference in October.

Despite the positive headlines there are issues in the study that are keeping some buyers cautious and causing selling into the early strength.

The two main issues are that the drug had failed in a prior study of 12-months duration. That has created some questions about why the 18-month period is showing different results. That brings up a second issue which is the measurement of cognitive improvement. Measuring stability of cognitive function over time is not an easy task and there will be some questions about the methodology employed.

The study shows the slowing progression of Alzheimer's but this is a far cry from a cure. The drug did have an impact but it will take years before we will know how positive this news will ultimately be.

Biogen is trading up about 16% or $48 on the news but is well under early levels that were $20 higher. Technically, the price action suggests further momentum after some profit taking and consolidation.

A good chart comparison is Sarepta Therapeutics (SRPT) which gapped up big on news in mid-June. The stock closed that day well off the intraday highs and has been consolidating for a few weeks now. It seems to have found support and there is accumulation as volume had dried up.

The SRPT niche is quite different than the BIIB situation but it does illustrate the risks of being too aggressive with chasing headlines that may overstate the situation.

I'll be looking to buy BIIB but I'm going to let the situation cool off a bit and see if it develops like SRPT has.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, James DePorre was Long SRPT.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login